ArticleFrontiers in immunology2026
An SPP1-centered immune-parenchymal communication axis links macrophage heterogeneity to ovarian cancer prognosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune and malignant epithelial cells shape each other through ligand-receptor signaling in ovarian cancer. SPP1 interacts with CD44 and several integrins, but its cellular organization and clinical relevance remain unclear. Methods: We integrated GSE184880 scRNA-seq data with TCGA-OV and three independent cohorts. Single-cell clustering, CNV inference, and cell communication analysis were used to characterize macrophage states and SPP1-related signaling. Based on the SPP1 ligand-receptor network identified by CellChat, an 11-gene set comprising SPP1 and its CD44/integrin receptor components was constructed and subsequently used for molecular subtyping. Four machine learning models were compared for prognostic prediction. PI3 was subsequently silenced in ES-2 and SKOV3 cells. SPP1 expression and secretion, cell proliferation, wound closure, migration, invasion, xenograft growth, and macrophage phenotypes after coculture were then evaluated. Results: Four macrophage states were identified: Resident Macro, Inflammatory Macro, SPP1+ TAM, and Activated Macro. Cell communication was extensively reorganized in ovarian tumors. SPP1+ TAM occupied a central position in the SPP1 network and communicated with malignant epithelial cells, fibroblasts, endothelial cells, and other macrophage populations through SPP1-CD44 and SPP1-integrin interactions. SPP1-related genes separated patients into SPP1-High and SPP1-Low subtypes. The SPP1-High subtype showed stronger immune- and cytokine-related activity and poorer overall survival. Among the four machine learning models, GBM-Cox achieved the highest C-index of 0.768 and maintained prognostic stratification across three independent cohorts. PI3 also ranked highly in several models. Silencing PI3 in tumor cells increased TNF, IL1B, CXCL10, and CD86 expression in cocultured macrophages, while reducing CD163, MRC1, CCL18, and IL10. Consistently, TNF-α and IL-12p70 levels increased, whereas IL-10 and CCL18 levels decreased. PI3 silencing reduced SPP1 mRNA expression and secretion and suppressed ovarian cancer cell proliferation, wound closure, migration, and invasion. Stable PI3 knockdown also delayed ES-2 xenograft growth and reduced terminal tumor volume and weight. Conclusion: The SPP1-associated ligand-receptor network represents an immune-parenchymal communication axis linking macrophages with malignant epithelial and stromal cells in ovarian cancer. This network captures differences in immune state and clinical outcome and supports both molecular classification and prognostic assessment. PI3 may contribute to tumor cell-mediated regulation of macrophage phenotype and could serve as a candidate biomarker or intervention target. PI3 may promote ovarian cancer progression while contributing to tumor-cell-derived SPP1 production and macrophage regulation, supporting its potential value as a candidate biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.